Display options
Cite
Khanna D, Distler O. Response to: 'Riociguat in systemic sclerosis: a potential for disease modification' by Jain and Dhir. Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-218194.
Khanna, D., & Distler, O. (2020). Response to: 'Riociguat in systemic sclerosis: a potential for disease modification' by Jain and Dhir. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-218194
Khanna, Dinesh, and Distler, Oliver. "Response to: 'Riociguat in systemic sclerosis: a potential for disease modification' by Jain and Dhir." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-218194
Khanna D, Distler O. Response to: 'Riociguat in systemic sclerosis: a potential for disease modification' by Jain and Dhir. Ann Rheum Dis. 2020 Jul 15; doi: 10.1136/annrheumdis-2020-218194. Epub 2020 Jul 15. PMID: 32669303.
Copy Download .nbib Format: NLM
Share it on

Ann Rheum Dis. 2020 Jul 15; doi: 10.1136/annrheumdis-2020-218194. Epub 2020 Jul 15.

Response to: 'Riociguat in systemic sclerosis: a potential for disease modification' by Jain and Dhir.

Annals of the rheumatic diseases

Dinesh Khanna, Oliver Distler

Affiliations

  1. Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA [email protected].
  2. Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland.

PMID: 32669303 DOI: 10.1136/annrheumdis-2020-218194

[No abstract available.]

Keywords: riociguat; skin fibrosis; systemic sclerosis

Conflict of interest statement

Competing interests: DK reports grant support from NIH, Immune Tolerance Network, Bayer AG, Bristol-Myers Squibb, Horizon, Pfizer; consultancy with Acceleron, Actelion, AbbVie, Amgen, Bayer AG, Boehri

Publication Types